MIH
DCOY

Meitav Investment House’s Decoy Therapeutics DCOY Stock Holding History

Meitav Investment House’s Portfolio DCOY Stock Details DCOY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1
Closed -$53K – 412
2021
Q3 		$53K Hold
1
– – ﹤0.01% 397
2021
Q2 		$55K Hold
1
– – ﹤0.01% 406
2021
Q1 		$77K Buy
+1
New +$57.3K ﹤0.01% 371

Other funds holding DCOY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
KC
Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
XSC
X-Square Capital Guaynabo, Puerto Rico $394M AUM 44.75% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Meitav Investment House's DCOY Position: Q4 2021 in Review

Meitav Investment House sold out of Decoy Therapeutics (DCOY) in Q4 2021, closing a stake of 1 share — an estimated $53K sold.

Meitav Investment House first reported a position in DCOY in Q1 2021 and held it in 3 quarters. The position peaked at $77K in Q1 2021. 17 funds tracked by Wall St. Rank hold DCOY as of Q4 2021.

  • Meitav Investment House reported no remaining Decoy Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Meitav Investment House sold 1 Decoy Therapeutics share in Q4 2021, an estimated $53K.
  • Meitav Investment House first reported a position in Decoy Therapeutics in Q1 2021 and held it in 3 quarters.
  • Meitav Investment House's Decoy Therapeutics position peaked at $77K in Q1 2021.
  • 17 funds tracked by Wall St. Rank held Decoy Therapeutics as of Q4 2021.

Based on Meitav Investment House's 13F filing for Q4 2021, filed 8 Feb 2022.